PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS was delisted on the 2nd of November, 2022.
61 hedge funds and large institutions have $110M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 22 increasing their positions, 17 reducing their positions, and 7 closing their positions.
108% more capital invested
Capital invested by funds: $53M → $110M (+$57.1M)
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
29% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 17
10% more call options, than puts
Call options by funds: $227K | Put options by funds: $206K
5% more funds holding
Funds holding: 58 → 61 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$17.4M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$13M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$11.6M |
| 4 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$8.78M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$371K |
| 2 |
Renaissance Technologies
New York
|
-$280K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$203K |
| 4 |
Millennium Management
New York
|
-$187K |
| 5 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$133K |
PHAS Hedge Fund Activity: Q1 2021 in Review
61 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) for Q1 2021, worth a combined $110M — up 108% from $53M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new PHAS positions and 7 closed out — a net gain of 4 holders — while 22 added to existing stakes and 17 trimmed.
The largest buyer was Avidity Partners Management, opening a new position worth an estimated $17.4M. The largest seller was Parkman Healthcare Partners, exiting entirely with an estimated $371K sold.
- 61 institutional investors held PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) as of Q1 2021, up from 58 in Q4 2020.
- Funds reported $110M of PhaseBio Pharmaceuticals, Inc. Common Stock stock for Q1 2021, up 108% quarter-over-quarter.
- 11 funds opened new PhaseBio Pharmaceuticals, Inc. Common Stock positions in Q1 2021 and 7 closed out, a net change of +4 holders.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock buyer in Q1 2021 was Avidity Partners Management, an estimated $17.4M added.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock seller in Q1 2021 was Parkman Healthcare Partners, an estimated $371K sold.
Based on aggregated 13F filings for Q1 2021.